- Home
- GILT vs CSTL Comparison
GILT vs CSTL Comparison
Compare GILT & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILT
- CSTL
- Stock Information
- Founded
- GILT 1987
- CSTL 2007
- Country
- GILT Israel
- CSTL United States
- Employees
- GILT N/A
- CSTL N/A
- Industry
- GILT Radio And Television Broadcasting And Communications Equipment
- CSTL Medical Specialities
- Sector
- GILT Technology
- CSTL Health Care
- Exchange
- GILT Nasdaq
- CSTL Nasdaq
- Market Cap
- GILT 797.0M
- CSTL 661.7M
- IPO Year
- GILT 1993
- CSTL 2019
- Fundamental
- Price
- GILT $13.45
- CSTL $34.89
- Analyst Decision
- GILT Strong Buy
- CSTL Strong Buy
- Analyst Count
- GILT 1
- CSTL 6
- Target Price
- GILT $11.00
- CSTL $38.67
- AVG Volume (30 Days)
- GILT 825.0K
- CSTL 436.0K
- Earning Date
- GILT 11-12-2025
- CSTL 11-03-2025
- Dividend Yield
- GILT N/A
- CSTL N/A
- EPS Growth
- GILT 42.22
- CSTL N/A
- EPS
- GILT 0.41
- CSTL N/A
- Revenue
- GILT $392,826,000.00
- CSTL $343,530,000.00
- Revenue This Year
- GILT $47.18
- CSTL N/A
- Revenue Next Year
- GILT $13.80
- CSTL N/A
- P/E Ratio
- GILT $31.76
- CSTL N/A
- Revenue Growth
- GILT 29.68
- CSTL 10.15
- 52 Week Low
- GILT $4.86
- CSTL $14.59
- 52 Week High
- GILT $15.24
- CSTL $35.49
- Technical
- Relative Strength Index (RSI)
- GILT 50.95
- CSTL 83.20
- Support Level
- GILT $12.27
- CSTL $32.51
- Resistance Level
- GILT $14.58
- CSTL $35.49
- Average True Range (ATR)
- GILT 0.57
- CSTL 1.66
- MACD
- GILT -0.23
- CSTL 0.97
- Stochastic Oscillator
- GILT 43.53
- CSTL 94.91
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.